Niraparib clinical trials
Also written Zejula, MK-4827 and JNJ-64091742.
ClinicalTrials.gov finds 238 studies for niraparib. How that becomes 151 here
Every study that search finds has been read, to see whether and how it gives niraparib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count
- 238Found by its intervention search · See all 238 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 215 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −1
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate CancerNCT03871816 · Screening for later studies; not givenReport a problem
- 237Give niraparib to participants
- −25Observe patients on it, or give it outside a trial
- −2Use it as a tool: an imaging tracer or a test of drug response
- −59Give it beside what is tested
- 151Test it: the count on this site
Get an email when these change. Save the niraparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Mar 2017 · ZEJULA · NDA 208447 (FDA, Drugs@FDA)
- European Union
- 16 Nov 2017 · Zejula · EMEA/H/C/004249 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
151 studies that test it; most in 2019 (24)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 5 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 9 |
| 2018 | 12 |
| 2019 | 24 |
| 2020 | 20 |
| 2021 | 19 |
| 2022 | 12 |
| 2023 | 17 |
| 2024 | 12 |
| 2025 | 6 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 43 · Other 108
Tesaro, Inc. (18) · Janssen Research & Development, LLC (5) · Massachusetts General Hospital (5) · GlaxoSmithKline (5) · Zai Lab (Shanghai) Co., Ltd. (5) · Hoffmann-La Roche (3) · Abramson Cancer Center at Penn Medicine (3) · M.D. Anderson Cancer Center (3)
Often tested with
Tested in the same studies.
Dostarlimab (20) · Atezolizumab (9) · Abiraterone (7) · Trastuzumab (7) · Abiraterone Acetate (6) · Cobimetinib (6) · Prednisone (6) · Olaparib (6)
Related medicines
As reviewed, each with the page that says it.
- One of PARP inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 8 most studied
New when their studies opened, with niraparib beside them; studies of each.
- 13Dostarlimab
- 3Anlotinib
- 2Tuvusertib
- 1Cetrelimab
- 1DNA Polymerase Theta Inhibitor GSK4524101
- 1Oregovomab
- 1Bemcentinib
- 1Azenosertib
Reaching primary completion within a year · 22, 4 in phase 3
Studies that test niraparib, phase 3 first.
- Nov 2026A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerPhase 3 · Tesaro, Inc.
- Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPhase 3 · Karolinska Institutet
- Jun 2027Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibPhase 2/3 · ARCAGY/ GINECO GROUP
- Jun 2027Personalized Medicine for Advanced Biliary Cancer PatientsPhase 3 · UNICANCER
- Nov 2026Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaPhase 2 · H. Lee Moffitt Cancer Center and Research Institute
- Dec 2026Niraparib and Temozolomide in Patients GlioblastomaPhase 1/2 · Armando Santoro, MD
- Dec 2026Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCPhase 2 · ETOP IBCSG Partners Foundation
- Dec 2026Niraparib in Tumors Metastatic to the CNSPhase 2 · Massachusetts General Hospital
- Dec 2026A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyPhase 2 · GlaxoSmithKline
- Dec 2026A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsPhase 1 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses niraparib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 151
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT06747845With ipilimumab against FOLFIRI in pancreatic cancerWritten as NiraparibReport a problem
- Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT06141265Maintenance after chemotherapy and bevacizumab in HRD ovarianWritten as NiraparibReport a problem
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingPhase 2/3ARCAGY/ GINECO GROUPNCT03651206Alone or with dostarlimab against chemotherapy in carcinosarcomaWritten as NiraparibReport a problem
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366With hormone therapy in one biomarker groupWritten as Niraparib 100mg Oral CapsuleReport a problem
- Study Evaluating Safety, Tolerability, and Metabolism of NiraparibRecruitingPhase 4University of MiamiNCT06412120Safety and metabolism as maintenanceWritten as NiraparibReport a problem
- SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi TherapyRecruitingPhase 2Institute of Cancer Research, United KingdomNCT05990192After SBRT against SBRT alone in ovarian cancerWritten as Niraparib oral capsuleReport a problem
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingPhase 2GlaxoSmithKlineNCT04641247Continued in a long-term extensionWritten as NiraparibReport a problem
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04947254Added with abiraterone to apalutamide, ADT and radiationWritten as NiraparibReport a problem
- Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCRecruitingPhase 2ETOP IBCSG Partners FoundationNCT05718323Added to anti-PD-L1 maintenance in small cell lung cancerWritten as NiraparibReport a problem
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818One matched option in biliary cancerWritten as NiraparibReport a problem
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440With fulvestrant in one breast platform substudyWritten as NiraparibReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Alone in one I-SPY arm before breast surgeryWritten as Dan222 + NiraparibReport a problem
- Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic ProgressionRecruitingPhase 2MedSIRNCT06180356Rechallenge after surgery in oligometastatic ovarian cancerWritten as Niraparib oral tabletsReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One PARP option in a salivary cancer cohortReport a problem
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05700721Alone or with dostarlimab in advanced cancersWritten as NiraparibReport a problem
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05526989With dostarlimab in penile carcinomaWritten as NiraparibReport a problem
- Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast CancerRecruitingPhase 2Nagoya City UniversityNCT06535893With pembrolizumab after chemotherapy in one breast armReport a problem
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181One matched drug in a profiling trialWritten as NiraparibReport a problem
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835One biomarker-assigned treatment in prostate cancerWritten as Niraparib plus Abiraterone acetate plus PrednisoneReport a problem
- A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)RecruitingPhase 1/2Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT06594679With abemaciclib in late-line ovarian cancerWritten as Niraparib Tosylate MonohydrateReport a problem
See all 151 studies that test niraparib →
Behind its US label · 2 — the studies the FDA label of ZEJULA describes
From the Clinical Studies section of ZEJULA (2026-07), as openFDA has it. A study the site does not hold is left out.
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerCompletedPhase 3Tesaro, Inc.NCT01847274Report a problem
- A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyActive, not recruitingPhase 3Tesaro, Inc.NCT02655016Report a problem
Tested on its own · 67 — no other medicine in its arm
- Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT06141265Maintenance after chemotherapy and bevacizumab in HRD ovarianWritten as NiraparibReport a problem
- Study Evaluating Safety, Tolerability, and Metabolism of NiraparibRecruitingPhase 4University of MiamiNCT06412120Safety and metabolism as maintenanceWritten as NiraparibReport a problem
- SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi TherapyRecruitingPhase 2Institute of Cancer Research, United KingdomNCT05990192After SBRT against SBRT alone in ovarian cancerWritten as Niraparib oral capsuleReport a problem
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingPhase 2GlaxoSmithKlineNCT04641247Continued in a long-term extensionWritten as NiraparibReport a problem
- Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCRecruitingPhase 2ETOP IBCSG Partners FoundationNCT05718323Added to anti-PD-L1 maintenance in small cell lung cancerWritten as NiraparibReport a problem
- Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic ProgressionRecruitingPhase 2MedSIRNCT06180356Rechallenge after surgery in oligometastatic ovarian cancerWritten as Niraparib oral tabletsReport a problem
- A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian CancerNot yet recruitingPhase 4GlaxoSmithKlineNCT06887933Safety of tablets in ovarian cancerWritten as NiraparibReport a problem
- Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination DeficiencyNot yet recruitingPhase 2Korea University Anam HospitalNCT06237205Alone in HRR-mutated solid tumoursWritten as NiraparibReport a problem
- Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous CarcinomaRecruitingPhase 2Shandong UniversityNCT04716686Maintenance or treatment in endometrial serous carcinomaWritten as NiraparibReport a problem
- Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian CancerRecruitingPhase 2Sunnybrook Health Sciences CentreNCT05961124Alternative dosing in first-line ovarian maintenanceWritten as NiraparibReport a problem
- A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCErNot yet recruitingPhase 1/2Institut Paoli-CalmettesNCT05519670With capecitabine in HER2-negative breast cancerWritten as Niraparib Oral ProductReport a problem
- Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNot yet recruitingPhase 2Zhejiang Cancer HospitalNCT05461690Alone in HRD triple-negative breast cancerWritten as NiraparibReport a problem
- PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT05232006Alone in PALB2-mutated breast cancerWritten as NiraparibReport a problem
- PARP Inhibitor Oral Maintenance in Low-Risk Ovarian CancerNot yet recruitingPhase 4Seoul National University HospitalNCT05187208Maintenance in low-risk BRCA wild-type ovarian cancerWritten as NiraparibReport a problem
- A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNAActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05515575Alone in soft tissue sarcoma with DNA changesWritten as NiraparibReport a problem
- Niraparib in Tumors Metastatic to the CNSActive, not recruitingPhase 2Massachusetts General HospitalNCT04992013Alone in tumours metastatic to the brainWritten as NiraparibReport a problem
- A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated GlioblastomaActive, not recruitingPhase 3Ivy Brain Tumor CenterNCT06388733Against temozolomide in MGMT-unmethylated glioblastomaWritten as NiraparibReport a problem
- A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsActive, not recruitingPhase 1Massachusetts General HospitalNCT03945721With radiotherapy after triple-negative breast surgeryWritten as NiraparibReport a problem
- Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response DefectsTerminatedPhase 2University of California, DavisNCT04030559Alone before prostate surgeryWritten as NiraparibReport a problem
- Niraparib in Patients With Pancreatic CancerCompletedPhase 2Dana-Farber Cancer InstituteNCT03601923Alone in pancreatic cancerWritten as NiraparibReport a problem
Showing 20 of 67. See all 67 →
Tested with established drugs · 12 — they are given beside it
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04947254Added with abiraterone to apalutamide, ADT and radiationWritten as NiraparibReport a problem
- Niraparib In Recurrent IDH 1/2 GliomasActive, not recruitingEarly Phase 1Massachusetts General HospitalNCT05406700Before resection in recurrent IDH gliomasWritten as NiraparibReport a problem
- Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringCompletedPhase 1/2NRG OncologyNCT04037254Added to hormone therapy and radiation in prostate cancerWritten as NiraparibReport a problem
- A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal CancersTerminatedPhase 1University of IowaNCT04926324With dostarlimab added to rectal radiotherapyWritten as NiraparibReport a problem
- Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerCompletedPhase 3GlaxoSmithKlineNCT04475939Added to pembrolizumab maintenance in lung cancerWritten as NiraparibReport a problem
- Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedPhase 1/2Tesaro, Inc.NCT02657889With pembrolizumab in breast or ovarian cancerWritten as niraparibReport a problem
- Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian CancerCompletedPhase 1/2Nordic Society of Gynaecological Oncology - Clinical Trials UnitNCT02354131Alone or with bevacizumab in ovarian cancerWritten as NiraparibReport a problem
- LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast CancerWithdrawnPhase 1Wake Forest University Health SciencesNCT04762901With chemotherapy in triple-negative breast cancer, doses foundWritten as NiraparibReport a problem
- ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing SarcomaCompletedPhase 1Sarcoma Alliance for Research through CollaborationNCT02044120With temozolomide or irinotecan in Ewing sarcomaWritten as niraparibReport a problem
- Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)TerminatedPhase 1Paul Mathew, MDNCT02500901With enzalutamide in prostate cancerWritten as NiraparibReport a problem
- MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)TerminatedPhase 1Tesaro, Inc.NCT01227941With liposomal doxorubicin in solid tumoursWritten as MK-4827 + pegylated liposomal doxorubicinReport a problem
- Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)CompletedPhase 1Merck Sharp & Dohme LLCNCT01294735With temozolomide in advanced cancerWritten as MK-4827Report a problem
Tested in a combination · 72 — another drug in the study is under test too
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT06747845With ipilimumab against FOLFIRI in pancreatic cancerWritten as NiraparibReport a problem
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingPhase 2/3ARCAGY/ GINECO GROUPNCT03651206Alone or with dostarlimab against chemotherapy in carcinosarcomaWritten as NiraparibReport a problem
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366With hormone therapy in one biomarker groupWritten as Niraparib 100mg Oral CapsuleReport a problem
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818One matched option in biliary cancerWritten as NiraparibReport a problem
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440With fulvestrant in one breast platform substudyWritten as NiraparibReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Alone in one I-SPY arm before breast surgeryWritten as Dan222 + NiraparibReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One PARP option in a salivary cancer cohortReport a problem
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05700721Alone or with dostarlimab in advanced cancersWritten as NiraparibReport a problem
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05526989With dostarlimab in penile carcinomaWritten as NiraparibReport a problem
- Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast CancerRecruitingPhase 2Nagoya City UniversityNCT06535893With pembrolizumab after chemotherapy in one breast armReport a problem
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181One matched drug in a profiling trialWritten as NiraparibReport a problem
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835One biomarker-assigned treatment in prostate cancerWritten as Niraparib plus Abiraterone acetate plus PrednisoneReport a problem
- A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)RecruitingPhase 1/2Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT06594679With abemaciclib in late-line ovarian cancerWritten as Niraparib Tosylate MonohydrateReport a problem
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Alone or with sintilimab in matched arms for rare tumoursReport a problem
- Niraparib and Temozolomide in Patients GlioblastomaNot yet recruitingPhase 1/2Armando Santoro, MDNCT06258018With temozolomide in glioblastomaWritten as NiraparibReport a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956Off-label in a precision medicine trialReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One matched drug in the DRUP trialWritten as NiraparibReport a problem
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingPhase 2University Health Network, TorontoNCT05065021Biomarker-chosen retreatment after a PARP inhibitorWritten as NiraparibReport a problem
- Niraparib and Dostarlimab in HRD Solid TumorsRecruitingPhase 2West Cancer CenterNCT04983745With dostarlimab in HRD solid tumoursReport a problem
- Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCCRecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT04681469With immunotherapy in head and neck cancerWritten as NiraparibReport a problem
Showing 20 of 72. See all 72 →
Beside an established treatment under test · 8 — an approved drug, surgery or radiation is what the study tests
Tested with niraparib: Bevacizumab 2 · Surgery or a procedure 2 · atezolizumab 1 · Cisplatin 1 · Radiation 1
- A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line TherapyRecruitingPhase 2North Eastern German Society of Gynaecological OncologyNCT05460000Maintenance in every arm; chemotherapy cycles comparedReport a problem
- Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerRecruitingPhase 3GOG FoundationNCT05659381Maintenance after the HIPEC being testedReport a problem
- Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian CancerRecruitingPhase 2ARCAGY/ GINECO GROUPNCT05183984In every armEvery arm takes it while bevacizumab is addedWritten as NiraparibReport a problem
- Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian CancerRecruitingPhase 3AGO Study GroupNCT05009082In every armEvery arm takes it while bevacizumab is addedWritten as NiraparibReport a problem
- Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate CancerRecruitingPhase 3Universitaire Ziekenhuizen KU LeuvenNCT06585007One standard option; metastasis-directed therapy is addedReport a problem
- Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)RecruitingPhase 2Shanghai Gynecologic Oncology GroupNCT03983226In every armMaintenance after surgery or chemotherapy; surgery is studiedWritten as NiraparibReport a problem
- Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A MutationTerminatedPhase 2University of OklahomaNCT05523440In every armEvery arm takes it while bevacizumab is addedWritten as NiraparibReport a problem
- Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian CancerCompletedPhase 3Grupo Español de Investigación en Cáncer de OvarioNCT03598270In every armEvery arm takes chemotherapy and niraparib; atezolizumab is addedWritten as NiraparibReport a problem
Beside a new treatment under test · 48 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with niraparib: dostarlimab 13 · anlotinib 3 · tuvusertib 2 · cetrelimab 1 · DNA Polymerase Theta Inhibitor GSK4524101 1 · oregovomab 1 · bemcentinib 1 · azenosertib 1
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 3ImunonNCT06915025In every armStandard maintenance option; new IMNN-001 is addedWritten as NiraparibReport a problem
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid TumorsRecruitingPhase 1/2Wigen Biomedicine Technology (Shanghai) Co., Ltd.NCT06953323One PARP partner for new WJB001Report a problem
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingPhase 1/2LaNova Medicines LimitedNCT06682780Partner option for new LM-2417Written as NiraparibReport a problem
- Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian CancerNot yet recruitingPhase 2/3Shanghai Municipal Hospital of Traditional Chinese MedicineNCT07550205One standard maintenance option; herbal granules are studiedReport a problem
- Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian CancerNot yet recruitingNot applicableRuijin HospitalNCT05749211Background maintenance; Huaier granule is addedReport a problem
- Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)CompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT04170153Partner of new tuvusertib in one partWritten as NiraparibReport a problem
- Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04701307In every armPartner of new dostarlimab in neuroendocrine cancersWritten as NiraparibReport a problem
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2Janssen Research & Development, LLCNCT03431350In every armPartner of new cetrelimab, or with abirateroneWritten as Niraparib 200 mgReport a problem
- Niraparib + Dostarlimab In BRCA Mutated Breast CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT04584255In every armPartner of new dostarlimab in BRCA breast cancerWritten as NiraparibReport a problem
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT06433219Partner of new tuvusertibWritten as NiraparibReport a problem
- Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04592237In every armBoth arms take it after induction; cetrelimab is addedWritten as NiraparibReport a problem
- Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic CancerCompletedPhase 2Mayo ClinicNCT04493060In every armPartner of new dostarlimab in pancreatic cancerWritten as NiraparibReport a problem
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedPhase 2University of LeicesterNCT03654833Partner of new dostarlimab in one mesothelioma armWritten as Dostarlimab and NiraparibReport a problem
- Study of Niraparib and TSR-042 in Recurrent Endometrial CancerActive, not recruitingPhase 2University Health Network, TorontoNCT03016338In every armPartner of new dostarlimab in endometrial cancerWritten as NiraparibReport a problem
- Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian CancerWithdrawnPhase 1University of Alabama at BirminghamNCT04149145In every armPartner of new M4344Written as M4344+NiraparibReport a problem
- Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCCCompletedPhase 2Trisha Wise-DraperNCT04313504In every armPartner of new dostarlimab in head and neck cancerWritten as NiraparibReport a problem
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid TumorsActive, not recruitingPhase 1/2GlaxoSmithKlineNCT06077877Partner of new GSK4524101Written as NiraparibReport a problem
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingPhase 2CanariaBio Inc.NCT05335993In every armPartner of new oregovomabWritten as NiraparibReport a problem
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedPhase 1/2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05198804Partner of new azenosertibWritten as NiraparibReport a problem
- Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerActive, not recruitingPhase 2University of OklahomaNCT04068753In every armPartner of new dostarlimab in cervical cancerWritten as NiraparibReport a problem
Showing 20 of 48. See all 48 →
Beside supportive care · 3 — a supportive treatment or test is studied
- The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer PatientsNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06036966Background maintenance; hetrombopag prevents its thrombocytopeniaReport a problem
- A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian CancerNot yet recruitingPhase 2Sichuan Cancer Hospital and Research InstituteNCT05641506In every armBackground maintenance; capsule tested against its nauseaWritten as NiraparibReport a problem
- 18F-FluorThanatrace (PET/CT) in GlioblastomaTerminatedEarly Phase 1University of PennsylvaniaNCT04221061Treatment given before a PET tracer is studiedReport a problem
Observed · 25 — patients on it are followed, or it is given outside a trial
- Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian CancerRecruitingFudan UniversityNCT07783022Real-world first-line maintenanceWritten as Niraparib (Tablet)Report a problem
- Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian CancerRecruitingHospices Civils de LyonNCT06572735Among PARP inhibitors, dose intensity in practiceReport a problem
- Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian CancerNot yet recruitingClinica Universidad de Navarra, Universidad de NavarraNCT07059676Blood markers of response to maintenanceWritten as Zejula (Niraparib)Report a problem
- Niraparib Versus Bevacizumab As Maintenance Therapy in Patients with De Novo Ovarian Cancer Without Homologous Recombination DeficiencyRecruitingCentre Hospitalier Universitaire de NīmesNCT06827353Maintenance outcomes against bevacizumab without HRDWritten as maintenance therapy with niraparibReport a problem
- Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.RecruitingPomeranian Medical University SzczecinNCT06614790Maintenance outcomes in newly diagnosed ovarian cancerReport a problem
- A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of NiraparibRecruitingPeking Union Medical College HospitalNCT06037213Long-term use, patient-reported outcomesReport a problem
- Efficacy and Adverse Effects of Niraparib in Ovarian Cancer.Not yet recruitingFirst Affiliated Hospital Xi'an Jiaotong UniversityNCT05583799Real-world efficacy and side effectsReport a problem
- Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceRCompletedRoyal Marsden NHS Foundation TrustNCT04295577Maintenance in UK routine practiceReport a problem
- A Study of Niraparib in Patients With Ovarian Cancer in Clinical PracticeCompletedTakedaNCT05021562Side effects in routine practiceWritten as NiraparibReport a problem
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated PatientsCompletedNovartis PharmaceuticalsNCT07477756One later treatment after lutetium-177 PSMAReport a problem
- The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian CancerCompletedAsan Medical CenterNCT06086665Real-world use in Korean ovarian cancerWritten as NiraparibReport a problem
- Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)Approved for marketingJanssen Research & Development, LLCNCT05401214Pre-approval access to fixed-dose with abirateroneWritten as Niraparib plus Abiraterone Acetate (Nira/AA) combinationReport a problem
- A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin AmericaActive, not recruitingLatin American Cooperative Oncology GroupNCT05857397Outcomes in an expanded access programmeReport a problem
- A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South KoreaCompletedTakedaNCT04589039Post-marketing surveillance in approved usesReport a problem
- Arterial Hypertension Related to PARP Inhibitors (ArteRIB)CompletedUniversity Hospital, CaenNCT04774406Hypertension under any PARP inhibitorWritten as olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparibReport a problem
- Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world StudyCompletedZhongda HospitalNCT05734911Real-world first-line maintenance in ChinaWritten as NiraparibReport a problem
- Pancytopenia Related to PARP Inhibitors (PancytoRIB)CompletedUniversity Hospital, CaenNCT04774627Among PARP inhibitors, pancytopenia observedReport a problem
- Homologous Recombination Deficiency in Chinese Ovarian Cancer PatientsStatus unknownXiaoxiang ChenNCT05044091Among PARP inhibitors, HRD in Chinese ovarian cancerReport a problem
- Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life StudyStatus unknownFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT04617470Real-life maintenance in ovarian cancerReport a problem
- Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian CancerCompletedGrupo Español de Investigación en Cáncer de OvarioNCT04546373Maintenance outcomes from the Spanish access programmeWritten as NiraparibReport a problem
Showing 20 of 25. See all 25 →
As a tool · 2 — an imaging tracer or a test of drug response
- Implantable Microdevice In Primary Brain TumorsRecruitingEarly Phase 1Oliver JonasNCT04135807One drug in a microdevice measuring local responseReport a problem
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerRecruitingPhase 1Brigham and Women's HospitalNCT04701645A microdose in an implanted deviceReport a problem
Codes
What other systems call niraparib · ClinicalTrials.gg INT005538
- MeSH (NLM) C545685niraparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) HMC2H89N35NIRAPARIBConfirmed FDA, NLM, Wikidata
- RxNorm 1918231Confirmed FDA, Wikidata
- Wikidata Q25326660niraparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80059NiraparibConfirmed FDA, Wikidata
- DrugBank DB11793One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545685 | niraparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | HMC2H89N35 | NIRAPARIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1918231 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25326660 | niraparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80059 | Niraparib | Confirmed FDA, Wikidata |
| DrugBank | DB11793 | — | One source Wikidata |
Also registered as niraparib hydrochloride (UNII L4JFC1PHCI) and niraparib tosylate (UNII 195Q483UZD).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.